MediWound (NASDAQ:MDWD – Get Free Report) and Hero Technologies (OTCMKTS:HENC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.
Institutional and Insider Ownership
22.3% of MediWound shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 0.2% of Hero Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for MediWound and Hero Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 0 | 0 | 4 | 0 | 3.00 |
| Hero Technologies | 0 | 0 | 0 | 0 | N/A |
Volatility and Risk
MediWound has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Hero Technologies has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
Valuation and Earnings
This table compares MediWound and Hero Technologies’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $26.50 million | 2.50 | -$19.60 million | ($2.43) | -2.96 |
| Hero Technologies | N/A | N/A | -$540,000.00 | N/A | N/A |
Hero Technologies has lower revenue, but higher earnings than MediWound.
Profitability
This table compares MediWound and Hero Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -55.53% | -71.45% | -27.28% |
| Hero Technologies | N/A | N/A | -372.58% |
Summary
MediWound beats Hero Technologies on 7 of the 10 factors compared between the two stocks.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
About Hero Technologies
Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
